Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but ...
Combination of ZG005 with etoposide and cisplatin (EP) vs. EP as the first-line therapy for advanced neuroendocrine carcinoma: A randomized, multicenter, phase I/II trial. This is an ASCO Meeting ...
Radiographic response of desmoplastic mesenteric lesions to peptide receptor radionuclide therapy (PRRT). This is an ASCO Meeting Abstract from the 2021 Gastrointestinal Cancers Symposium. This ...
A new type of peptide receptor radionuclide therapy (PRRT) has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission in some ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results